ATE71289T1 - Paucilamellare lipidvesikel. - Google Patents

Paucilamellare lipidvesikel.

Info

Publication number
ATE71289T1
ATE71289T1 AT88903062T AT88903062T ATE71289T1 AT E71289 T1 ATE71289 T1 AT E71289T1 AT 88903062 T AT88903062 T AT 88903062T AT 88903062 T AT88903062 T AT 88903062T AT E71289 T1 ATE71289 T1 AT E71289T1
Authority
AT
Austria
Prior art keywords
lipid vesicles
paucilamellar lipid
vesicles
paucilamellar
wax
Prior art date
Application number
AT88903062T
Other languages
English (en)
Inventor
Donald F H Wallach
Original Assignee
Micro Vesicular Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26699867&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE71289(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Micro Vesicular Systems filed Critical Micro Vesicular Systems
Application granted granted Critical
Publication of ATE71289T1 publication Critical patent/ATE71289T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D17/00—Detergent materials or soaps characterised by their shape or physical properties
    • C11D17/0008—Detergent materials or soaps characterised by their shape or physical properties aqueous liquid non soap compositions
    • C11D17/0017—Multi-phase liquid compositions
    • C11D17/0021—Aqueous microemulsions
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D17/00—Detergent materials or soaps characterised by their shape or physical properties
    • C11D17/0008—Detergent materials or soaps characterised by their shape or physical properties aqueous liquid non soap compositions
    • C11D17/0026—Structured liquid compositions, e.g. liquid crystalline phases or network containing non-Newtonian phase
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/10—Insect repellent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/812—Liposome comprising an antibody, antibody fragment, antigen, or other specific or nonspecific immunoeffector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/829—Liposomes, e.g. encapsulation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S525/00—Synthetic resins or natural rubbers -- part of the class 520 series
    • Y10S525/936—Encapsulated chemical agent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Fats And Perfumes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Road Signs Or Road Markings (AREA)
  • Cosmetics (AREA)
  • Excavating Of Shafts Or Tunnels (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT88903062T 1987-03-13 1988-03-08 Paucilamellare lipidvesikel. ATE71289T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2552587A 1987-03-13 1987-03-13
US07/157,571 US4911928A (en) 1987-03-13 1988-03-03 Paucilamellar lipid vesicles
PCT/US1988/000723 WO1988006883A1 (en) 1987-03-13 1988-03-08 Paucilamellar lipid vesicles
EP88903062A EP0352282B1 (de) 1987-03-13 1988-03-08 Paucilamellare lipidvesikel

Publications (1)

Publication Number Publication Date
ATE71289T1 true ATE71289T1 (de) 1992-01-15

Family

ID=26699867

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88903062T ATE71289T1 (de) 1987-03-13 1988-03-08 Paucilamellare lipidvesikel.

Country Status (14)

Country Link
US (1) US4911928A (de)
EP (1) EP0352282B1 (de)
JP (1) JP2589173B2 (de)
KR (1) KR960009647B1 (de)
AT (1) ATE71289T1 (de)
AU (1) AU605581B2 (de)
BR (1) BR8807410A (de)
CA (1) CA1289419C (de)
DE (1) DE3867637D1 (de)
DK (1) DK633388D0 (de)
HU (1) HUT53279A (de)
NO (1) NO885032L (de)
NZ (1) NZ223843A (de)
WO (1) WO1988006883A1 (de)

Families Citing this family (280)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023086A (en) * 1987-03-13 1991-06-11 Micro-Pak, Inc. Encapsulated ionophore growth factors
US5147723A (en) * 1987-07-28 1992-09-15 Micro-Pak, Inc. Paucilamellar lipid vesicles
US5474848A (en) * 1987-03-13 1995-12-12 Micro-Pak, Inc. Paucilamellar lipid vesicles
US5219538A (en) * 1987-03-13 1993-06-15 Micro-Pak, Inc. Gas and oxygen carrying lipid vesicles
US5234767A (en) * 1987-03-13 1993-08-10 Micro-Pak, Inc. Hybrid paucilamellar lipid vesicles
US5628936A (en) * 1987-03-13 1997-05-13 Micro-Pak, Inc. Hybrid paucilamellar lipid vesicles
JP2617346B2 (ja) * 1987-03-13 1997-06-04 マイクロ ベシキュラー システムズ，インコーポレイテッド 表面活性剤とステロイドから形成される脂質小胞
US5811119A (en) * 1987-05-19 1998-09-22 Board Of Regents, The University Of Texas Formulation and use of carotenoids in treatment of cancer
EP0324455A3 (de) * 1988-01-15 1991-03-27 Hans O. Ribi Neue polymerische Immuno-Adjuvans
US4895452A (en) * 1988-03-03 1990-01-23 Micro-Pak, Inc. Method and apparatus for producing lipid vesicles
US5019392A (en) * 1988-03-03 1991-05-28 Micro-Pak, Inc. Encapsulation of parasiticides
US5160669A (en) * 1988-03-03 1992-11-03 Micro Vesicular Systems, Inc. Method of making oil filled paucilamellar lipid vesicles
US5104736A (en) * 1988-03-03 1992-04-14 Micro-Pak, Inc. Reinforced paucilamellar lipid vesicles
US5032457A (en) * 1988-03-03 1991-07-16 Micro Vesicular Systems, Inc. Paucilamellar lipid vesicles using charge-localized, single chain, nonphospholipid surfactants
US5013497A (en) * 1988-03-03 1991-05-07 Micro-Pak, Inc. Method and apparatus for producing lipid vesicles
US5019174A (en) * 1988-03-03 1991-05-28 Micro Vesicular Systems, Inc. Removing oil from surfaces with liposomal cleaner
US4906476A (en) * 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
US5510117A (en) * 1989-03-09 1996-04-23 Micro-Pak, Inc. Entrapment vehicle and method
GB8906234D0 (en) * 1989-03-17 1989-05-04 Albright & Wilson Agrochemical suspensions
AU6524990A (en) * 1989-09-21 1991-04-18 Micro Vesicular Systems, Inc. Hybrid paucilamellar lipid vesicles
US5227165A (en) * 1989-11-13 1993-07-13 Nova Pharmaceutical Corporation Liposphere delivery systems for local anesthetics
US5188837A (en) * 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
IE904098A1 (en) * 1989-11-13 1991-05-22 Nova Pharm Corp Lipospheres for controlled delivery of substances
FR2657607B1 (fr) * 1990-01-30 1992-04-30 Durand Muriel Procede de protection de la dihydroxyacetone, dihydroxyacetone protegee par ce procede et produit cosmetique contenant une telle dihydroxyacetone protegee.
US5213810A (en) * 1990-03-30 1993-05-25 American Cyanamid Company Stable compositions for parenteral administration and method of making same
US5165994A (en) * 1990-06-05 1992-11-24 University Of Delaware Spontaneous equilbrium surfactant vesicles
CA2046830C (en) 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
WO1992003123A1 (en) * 1990-08-28 1992-03-05 Liposome Technology, Inc. Liposome alternative bilayer formulations
ATE139691T1 (de) * 1990-09-06 1996-07-15 Johnson & Son Inc S C Verfahren zur stabilisierung von liposomen sowie diese enthaltende mittel
US5145604A (en) * 1990-09-19 1992-09-08 S. C. Johnson & Son, Inc. Aqueous emulsion and aerosol delivery system using same
US5091111A (en) * 1990-09-19 1992-02-25 S. C. Johnson & Son, Inc. Aqueous emulsion and aersol delivery system using same
AU654858B2 (en) * 1991-03-28 1994-11-24 Novavax, Inc. Lipid vesicle containing water-in-oil emulsions
US5256422A (en) * 1991-03-28 1993-10-26 Micro Vesicular Systems, Inc. Lipid vesicle containing water-in-oil emulsions
DE4121945C2 (de) * 1991-07-03 1993-11-04 Merz & Co Gmbh & Co Verfahren zur herstellung von stabilen, hydrophilen oder ambiphilen creme-zubereitungen, enthaltend vesikulaere bestandteile, stabile creme-zubereitungen mit vesikulaeren bestandteilen und deren verwendung
US5213805A (en) * 1991-07-25 1993-05-25 Micro Vesicular Systems, Inc. Lipid vesicles having n,n-dimethylamide derivatives as their primary lipid
US5260065A (en) * 1991-09-17 1993-11-09 Micro Vesicular Systems, Inc. Blended lipid vesicles
US5405615A (en) * 1991-09-17 1995-04-11 Micro Vesicular Systems, Inc. Sucrose distearate lipid vesicles
US5643600A (en) * 1991-09-17 1997-07-01 Micro-Pak, Inc. Lipid vesicles containing avocado oil unsaponifiables
US5439967A (en) * 1991-09-17 1995-08-08 Micro Vesicular Systems, Inc. Propylene glycol stearate vesicles
AU5611894A (en) * 1992-12-02 1994-06-22 Micro Vesicular Systems, Inc. Extended duration antacid product
US5393527A (en) * 1993-01-04 1995-02-28 Becton, Dickinson And Company Stabilized microspheres and methods of preparation
CA2153780C (en) * 1993-01-15 2004-04-13 Micro Vesicular Systems, Inc. Method of inhibiting viral reproduction
US5853755A (en) * 1993-07-28 1998-12-29 Pharmaderm Laboratories Ltd. Biphasic multilamellar lipid vesicles
DE69435244D1 (de) * 1993-12-17 2009-11-26 Novavax Inc Verfahren zur übertragung eines biologisch aktiven materials an eine zelle
JP3836874B2 (ja) * 1994-02-24 2006-10-25 ノババックス インコーポレイテッド 免疫アジュバントとして少ラメラ脂質小胞を含むワクチン
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
US5629021A (en) * 1995-01-31 1997-05-13 Novavax, Inc. Micellar nanoparticles
FR2730928B1 (fr) * 1995-02-23 1997-04-04 Oreal Composition a base de vesicules lipidiques a ph acide et son utilisation en application topique
US5599548A (en) * 1995-05-08 1997-02-04 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care compositions containing fatty acid amides and retinol or retinyl ester
US5954998A (en) * 1995-05-25 1999-09-21 The Clorox Company Liquid peracid precursor colloidal dispersions: oil-core vesicles
US5902604A (en) * 1995-06-06 1999-05-11 Board Of Regents, The University Of Texas System Submicron liposome suspensions obtained from preliposome lyophilizates
US5834014A (en) * 1995-10-06 1998-11-10 The Regents Of The University Of Michigan Stimulation of hair follicles
US6183774B1 (en) 1996-01-31 2001-02-06 Collaborative Laboratories, Inc. Stabilizing vitamin A derivatives by encapsulation in lipid vesicles formed with alkylammonium fatty acid salts
US6071535A (en) * 1996-01-31 2000-06-06 Collaborative Laboratories, Inc. Lipid vesicles formed with alkylammonium fatty acid salts
US5874105A (en) * 1996-01-31 1999-02-23 Collaborative Laboratories, Inc. Lipid vesicles formed with alkylammonium fatty acid salts
US5662957A (en) * 1996-05-03 1997-09-02 Novavax, Inc. Oil containing lipid vesicles with marine applications
US5700679A (en) * 1996-06-07 1997-12-23 Novavax, Inc. Lipid vesicles having a bilayer containing a surfactant with anti-viral and spermicidal activity
US5846551A (en) * 1996-06-10 1998-12-08 E-L Management Corp. Water-based makeup compositions and methods for their preparation
US5747051A (en) * 1996-09-27 1998-05-05 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care compositions containing an amide of a hydroxy fatty acid and a retinoid
US5955092A (en) * 1996-09-27 1999-09-21 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care compositions containing an n-substituted fatty acid amide and retinol or retinyl ester
US5935572A (en) * 1997-01-10 1999-08-10 Collaborative Laboratories, Inc. Composition containing protease separate from glycosidase for removing nits in treating lice infestation
US6039960A (en) 1997-05-28 2000-03-21 E-L Management Corp. Water containing wax-based product
IS4518A (is) * 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
US5993852A (en) * 1997-08-29 1999-11-30 Pharmaderm Laboratories Ltd. Biphasic lipid vesicle composition for transdermal administration of an immunogen
TW476788B (en) 1998-04-08 2002-02-21 Kimberly Clark Co A cleanser and the making process thereof
GB9824024D0 (en) * 1998-11-03 1998-12-30 Unilever Plc Shampoo compositions
HK1040629B (en) * 1998-12-23 2005-01-28 Idea Ag Improved formulations for local non-diffusive administration in vivo
PT1031347E (pt) 1999-01-27 2002-09-30 Idea Ag Transporte/imunizacao transnasal com veiculos muitissimo adaptaveis
SI1031346T1 (en) 1999-01-27 2002-08-31 Idea Ag Noninvasive vaccination through the skin
US6080211A (en) * 1999-02-19 2000-06-27 Igen, Inc. Lipid vesicle-based fuel additives and liquid energy sources containing same
CA2309373A1 (en) * 1999-05-27 2000-11-27 Johnson & Johnson Consumer Companies, Inc. Novel topical formulations
AU5409699A (en) * 1999-07-05 2001-01-22 Idea Ag A method for the improvement of transport across adaptable semi-permeable barriers
US6309664B1 (en) 1999-09-15 2001-10-30 Igen, Incorporated Methods, uses and compositions of fluid petrolatum
US6534078B1 (en) * 1999-10-18 2003-03-18 Natural Pest Fx, Inc. Micro-encapsulated pepper-mustard composition and methods of using the same
US6375968B1 (en) 1999-10-22 2002-04-23 3M Innovative Properties Company Encapsulated active material immobilized in hydrogel microbeads
US6376514B1 (en) 2000-10-17 2002-04-23 The Procter & Gamble Co. Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof
US6540991B2 (en) 2001-04-06 2003-04-01 3M Innovative Properties Company Stabilized active materials
US6562361B2 (en) 2001-05-02 2003-05-13 3M Innovative Properties Company Pheromone immobilized in stable hydrogel microbeads
AU2002353774A1 (en) * 2001-08-01 2003-03-24 The Procter And Gamble Company Products and methods for treating microbial infections
JP2005509598A (ja) * 2001-08-16 2005-04-14 リュフヤトルン・エイチエフ，バイオファーマシューティカルズ エクスビボで抗体を産生する方法
US6709663B2 (en) 2001-08-31 2004-03-23 Healthpoint, Ltd. Multivesicular emulsion drug delivery systems
DE60137229D1 (de) * 2001-10-22 2009-02-12 Viroblock Sa Non-phospholipid Vesikel (npLV) und ihre Verwendung in kosmetischen, therapeutischen und prophylaktischen Anwendungen
US20030129213A1 (en) * 2001-12-26 2003-07-10 Gonzalez Anthony D. Meta-stable insect repellent emulsion composition and method of use
US20030219465A1 (en) * 2002-05-23 2003-11-27 Suresh Kumar Gidwani Composition for delivery of dithranol
US20030232091A1 (en) * 2002-06-17 2003-12-18 Adi Shefer Stabilized retinol for cosmetic dermatological, and pharmaceutical compositions, and use thereof
US7473432B2 (en) * 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
US20040087564A1 (en) * 2002-10-31 2004-05-06 Wright D. Craig Delivery composition and method
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
EP1668024A4 (de) 2003-09-29 2008-07-02 Topigen Pharma Inc Oligonukleotidzusammensetzungen und verfahren zur behandlung von krankheiten einschliesslich entzündlicher leiden
KR100854832B1 (ko) * 2004-04-05 2008-08-27 각고우호우진 가나가와 다이가쿠 유화 분산제 및 이를 이용한 유화 분산 방법, 유화물, 및에멀젼 연료
EP1742534A4 (de) 2004-04-07 2011-04-13 Univ Georgia Wechselseitige glucosamin- und glucosamin/entzündungshemmende prodrugs, zusammensetzungen und verfahren
US8034796B2 (en) * 2004-04-07 2011-10-11 The University Of Georgia Research Foundation, Inc. Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods
JP4616602B2 (ja) * 2004-09-16 2011-01-19 大日本塗料株式会社 単分散粒子の製造方法
NZ554723A (en) 2004-10-29 2009-12-24 Topigen Pharmaceuticals Inc Antisense oligonucleotides against CCR3 chemokine receptor
EP1811961A2 (de) * 2004-11-12 2007-08-01 Idea Ag Erweiterte oberflächen-aggregate bei der behandlung von hauterkrankungen
DK2730277T3 (da) 2004-12-22 2020-04-06 Nitto Denko Corp Lægemiddelbærer og lægemiddelbærerkit til at inhibere fibrose
JP4533420B2 (ja) * 2004-12-22 2010-09-01 日東電工株式会社 線維化抑制のための薬物担体および薬物担体キット
US20120269886A1 (en) 2004-12-22 2012-10-25 Nitto Denko Corporation Therapeutic agent for pulmonary fibrosis
WO2006071659A1 (en) * 2004-12-29 2006-07-06 Trustees Of Boston University Delivery of h2 antagonists
CN101111306B (zh) 2005-01-28 2010-09-29 独立行政法人科学技术振兴机构 经脱水缩合反应可发生相转移的分子集合体及其相转移方法
EP1910297B1 (de) 2005-07-11 2016-05-25 Aerie Pharmaceuticals, Inc. Isochinolinverbindungen
WO2007041627A1 (en) 2005-10-03 2007-04-12 Pinsky Mark A Compositions and methods for improved skin care
BRPI0617486A2 (pt) 2005-10-18 2011-07-26 Novavax Inc vacina que compreende partÍculas similares a vÍrus da gripe funcionais (vlp) e uso de uma vlp de gripe
US9572886B2 (en) 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
KR20090035662A (ko) * 2006-05-19 2009-04-10 토피겐 파마슈티컬스 인코포레이티드 포스포디에스테라아제의 발현에 영향을 미치는 올리고누클레오티드
EA016073B1 (ru) * 2006-05-19 2012-01-30 Вайэроблок С.А. Композиция для инактивации оболочечного вируса (варианты), средства на ее основе для приготовления лекарства против вирусного заболевания, для приготовления больших количеств биосовместимого дезинфицирующего средства и для приготовления покрытия, содержащий ее набор для инактивации оболочечного вируса и способ инактивации оболочечного вируса
CA2664335C (en) * 2006-09-20 2014-12-02 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
JP5512280B2 (ja) * 2006-12-28 2014-06-04 スリーエム イノベイティブ プロパティズ カンパニー 歯科充填剤及び方法
US8455513B2 (en) * 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US20100098752A1 (en) * 2007-01-18 2010-04-22 Pinsky Mark A Materials and Methods for Delivering Antioxidants into the Skin
TWI407971B (zh) 2007-03-30 2013-09-11 Nitto Denko Corp Cancer cells and tumor-related fibroblasts
CA3056116A1 (en) 2007-06-22 2008-12-31 Randolph Watnick Methods and uses thereof of prosaposin
FR2917976B1 (fr) * 2007-06-29 2010-05-28 Galderma Sa Composition dermatologique comprenant des vehicules lipidiques de calcitriol, son procede de preparation et son utilisation
JP2010533737A (ja) 2007-07-19 2010-10-28 ノババックス，インコーポレイテッド キメラ水痘帯状疱疹ウイルス−ウイルス様粒子
AU2008345068A1 (en) * 2007-12-26 2009-07-09 Mark A. Pinsky Collagen formulations for improved skin care
US8455514B2 (en) * 2008-01-17 2013-06-04 Aerie Pharmaceuticals, Inc. 6-and 7-amino isoquinoline compounds and methods for making and using the same
US10251839B2 (en) * 2008-01-22 2019-04-09 Igi Laboratories, Inc. Lipid vesicles derived from olive oil fatty acids
CA2724179A1 (en) 2008-05-15 2009-11-19 Topigen Pharmaceuticals Inc. Oligonucleotides for treating inflammation and neoplastic cell proliferation
DK2789684T3 (en) 2008-05-23 2017-02-20 Siwa Corp Methods and compositions for facilitating regeneration
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
EP2369923B1 (de) * 2008-11-26 2016-06-22 Viroblock SA Verfahren zur hemmung von gram-positiv-bakterien unter verwendung von nicht-phospholipid-enthaltenden lipid-vesikeln
SI3067064T1 (sl) 2008-12-09 2020-09-30 Novavax, Inc. Modificirani RSV F proteini in postopki za njih uporabo
ES2834451T3 (es) 2009-05-01 2021-06-17 Aerie Pharmaceuticals Inc Inhibidores de mecanismo doble para el tratamiento de enfermedades
US20120245205A1 (en) 2009-07-29 2012-09-27 Delong Mitchell A Compositions and methods for inhibiting hair growth
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
CA2781527C (en) 2009-09-23 2017-10-24 Indu Javeri Methods for the preparation of liposomes
EP2513137B1 (de) 2009-12-17 2018-02-28 Children's Medical Center Corporation Aus saposin-a gewonnene peptide und verwendungen davon
EP2621534B1 (de) 2010-09-27 2019-03-13 Siwa Corporation Selektive entfernung von age-modifizierten zellen zur behandlung von atherosklerose
MX354750B (es) 2010-11-05 2018-03-20 Novavax Inc PARTÍCULAS PSEUDO-VIRALES (PPVs) QUE COMPRENDEN GLICOPROTEÍNAS DEL VIRUS DE LA RABIA.
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
WO2012075337A2 (en) 2010-12-01 2012-06-07 Spinal Modulation, Inc. Directed delivery of agents to neural anatomy
CA2839755A1 (en) 2011-06-17 2012-12-20 President And Fellows Of Harvard College Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer
CN104023717B (zh) 2011-06-29 2017-08-04 阿维达斯制药有限责任公司 包括脂质微胶囊递送媒剂的局部调配物和其用途
JP6261500B2 (ja) 2011-07-22 2018-01-17 プレジデント アンド フェローズ オブ ハーバード カレッジ ヌクレアーゼ切断特異性の評価および改善
CA2860226C (en) 2011-12-22 2022-10-18 Randolph S. Watnick Saposin-a derived peptides and uses thereof
US9737480B2 (en) 2012-02-06 2017-08-22 President And Fellows Of Harvard College ARRDC1-mediated microvesicles (ARMMs) and uses thereof
AU2013203395A1 (en) 2012-03-30 2013-10-17 Isis Pharmaceuticals, Inc. Compositions and methods for modulating TAU expression for reducing seizure and modifying a neurodegenerative syndrome
KR20150130430A (ko) 2013-03-14 2015-11-23 아이시스 파마수티컬즈 인코포레이티드 타우 발현을 조절하는 조성물 및 방법
ES2942898T3 (es) 2013-03-15 2023-06-07 Aerie Pharmaceuticals Inc Compuesto para uso en el tratamiento de trastornos oculares
WO2014152511A1 (en) 2013-03-15 2014-09-25 The Jackson Laboratory Methods for promoting wound healing and hair growth
US20140325490A1 (en) * 2013-04-25 2014-10-30 Hewlett-Packard Development Company, L.P. Classifying Source Code Using an Expertise Model
TWI657819B (zh) 2013-07-19 2019-05-01 美商Ionis製藥公司 用於調節τ蛋白表現之組合物
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
HK1225631A1 (zh) 2013-09-19 2017-09-15 Novavax, Inc. 免疫原性中东呼吸综合征冠状病毒(mers-cov)组合物和方法
US20150166985A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting von willebrand factor point mutations
WO2015097317A1 (es) * 2013-12-23 2015-07-02 Dermopartners, S.L. Procedimiento de preparación de liposomas de retinaldehido u otros precursores del ácido retinoico y producto así obtenido
CA2956224A1 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
WO2016036918A1 (en) 2014-09-03 2016-03-10 Boehringer Ingelheim International Gmbh Compound targeting il-23a and tnf-alpha and uses thereof
AU2015318036B2 (en) 2014-09-19 2021-07-01 Siwa Corporation Anti-AGE antibodies for treating inflammation and auto-immune disorders
US9816080B2 (en) 2014-10-31 2017-11-14 President And Fellows Of Harvard College Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
WO2016138287A1 (en) 2015-02-25 2016-09-01 Washington University METHODS TO DETECT MOTOR NEURON DISEASE COMPRISING MICRO-RNAs
MX2018000959A (es) 2015-07-23 2018-06-06 Boehringer Ingelheim Int Compuesto que se dirige a il-23a y al factor de activacion de linfocitos b (baff) y usos de estos.
KR102758377B1 (ko) 2015-09-03 2025-01-23 노바백스, 인코포레이티드 개선된 안정성 및 면역원성을 갖는 백신 조성물
MX2018004545A (es) 2015-10-13 2018-08-01 Siwa Corp Anticuerpos anti-age y metodos para utilizarlos.
IL294014B2 (en) 2015-10-23 2024-07-01 Harvard College Nucleobase editors and uses thereof
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
CN108601355B (zh) 2015-11-17 2021-03-30 爱瑞制药公司 制备激酶抑制剂及其中间体的方法
KR102536017B1 (ko) 2016-02-19 2023-05-24 시와 코퍼레이션 고급 당화 최종 산물(age)에 대한 항체를 사용하여 암을 치료하고, 전이성 암 세포를 사멸시키고, 암 전이를 예방하기 위한 방법 및 조성물
US10435682B2 (en) 2016-02-19 2019-10-08 University Of South Florida Arginine deiminase gene therapy for disordered proteins
EP3443007A1 (de) 2016-04-15 2019-02-20 Siwa Corporation Anti-age-antikörper zur behandlung von neurodegenerativen erkrankungen
AU2017277905B2 (en) 2016-06-08 2022-04-14 Children's Medical Center Corporation Engineered Botulinum neurotoxins
EP3475306A1 (de) 2016-06-23 2019-05-01 Siwa Corporation Impfstoffe zur verwendung bei der behandlung verschiedener erkrankungen und störungen
IL298102B2 (en) 2016-07-08 2025-09-01 Childrens Medical Center New botulinum neurotoxicant and its derivatives
SG11201900907YA (en) 2016-08-03 2019-02-27 Harvard College Adenosine nucleobase editors and uses thereof
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
CN106268551B (zh) * 2016-08-09 2018-11-20 中国石油大学(华东) 一种具有光捕获功能的多级复合微胶囊的制备方法
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
CN118873533A (zh) 2016-08-31 2024-11-01 爱尔康公司 眼用组合物
WO2018064593A1 (en) 2016-09-29 2018-04-05 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing tau expression
US11730823B2 (en) 2016-10-03 2023-08-22 President And Fellows Of Harvard College Delivery of therapeutic RNAs via ARRDC1-mediated microvesicles
KR20240007715A (ko) 2016-10-14 2024-01-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
WO2018119354A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Gene editing of pcsk9
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
CN110662556A (zh) 2017-03-09 2020-01-07 哈佛大学的校长及成员们 癌症疫苗
JP2020510439A (ja) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ シトシンからグアニンへの塩基編集因子
IL269458B2 (en) 2017-03-23 2024-02-01 Harvard College Nucleic base editors that include nucleic acid programmable DNA binding proteins
EP3609871A4 (de) 2017-03-31 2021-01-06 Aerie Pharmaceuticals, Inc. Aryl-cyclopropyl-amino-isochinolinyl-amidverbindungen
JP2020516648A (ja) 2017-04-13 2020-06-11 シワ コーポレーション ヒト化モノクローナル終末糖化産物抗体
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
JP7317796B2 (ja) 2017-07-24 2023-07-31 ノババックス，インコーポレイテッド 呼吸器疾患を治療するための方法および組成物
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
EP3687566A2 (de) 2017-09-29 2020-08-05 Children's Medical Center Corporation Neurotoxinähnliches toxin und dessen verwendungen
AU2018352592C1 (en) 2017-10-16 2025-09-25 Beam Therapeutics, Inc. Uses of adenosine base editors
US11541120B2 (en) 2017-12-05 2023-01-03 Anthos Partners, Lp Phosphonium-based ionic drug conjugates
EP3724214A4 (de) 2017-12-15 2021-09-01 The Broad Institute Inc. Systeme und verfahren zur vorhersage von reparaturergebnissen in der gentechnik
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
US10538553B2 (en) 2018-01-05 2020-01-21 University Of South Florida Compounds for the treatment of neurodegenerative diseases
WO2019168953A1 (en) 2018-02-27 2019-09-06 President And Fellows Of Harvard College Evolved cas9 variants and uses thereof
US10507226B1 (en) 2018-05-02 2019-12-17 University Of South Florida N-amino peptide beta-sheet mimics for the treatment of Alzheimer's disease
WO2019217943A1 (en) 2018-05-11 2019-11-14 Beam Therapeutics Inc. Methods of editing single nucleotide polymorphism using programmable base editor systems
EP3797160A1 (de) 2018-05-23 2021-03-31 The Broad Institute Inc. Baseneditoren und verwendungen davon
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
JP2021532114A (ja) 2018-07-23 2021-11-25 シワ コーポレーション 放射線曝露及び化学物質曝露の慢性影響を治療するための方法及び組成物
CA3108281A1 (en) 2018-08-03 2020-02-06 Beam Therapeutics Inc. Multi-effector nucleobase editors and methods of using same to modify a nucleic acid target sequence
US20240173430A1 (en) 2018-09-05 2024-05-30 The Broad Institute, Inc. Base editing for treating hutchinson-gilford progeria syndrome
US11427563B2 (en) 2018-09-14 2022-08-30 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
US20220282275A1 (en) 2018-11-15 2022-09-08 The Broad Institute, Inc. G-to-t base editors and uses thereof
WO2020154500A1 (en) 2019-01-23 2020-07-30 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
WO2020181195A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. T:a to a:t base editing through adenine excision
WO2020181180A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. A:t to c:g base editors and uses thereof
WO2020181193A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. T:a to a:t base editing through adenosine methylation
WO2020181202A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. A:t to t:a base editing through adenine deamination and oxidation
WO2020181178A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. T:a to a:t base editing through thymine alkylation
GB2601618B (en) 2019-03-19 2024-11-06 Broad Inst Inc Methods and compositions for editing nucleotide sequences
US20220204975A1 (en) 2019-04-12 2022-06-30 President And Fellows Of Harvard College System for genome editing
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
WO2020236982A1 (en) 2019-05-20 2020-11-26 The Broad Institute, Inc. Aav delivery of nucleobase editors
WO2020252455A1 (en) 2019-06-13 2020-12-17 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
WO2021025750A1 (en) 2019-08-08 2021-02-11 The Broad Institute, Inc. Base editors with diversified targeting scope
WO2021030666A1 (en) 2019-08-15 2021-02-18 The Broad Institute, Inc. Base editing by transglycosylation
AU2020345830A1 (en) 2019-09-09 2022-03-24 Beam Therapeutics Inc. Novel CRISPR enzymes, methods, systems and uses thereof
JP2022550130A (ja) 2019-09-26 2022-11-30 プレジデント アンド フェローズ オブ ハーバード カレッジ 最小アレスチンドメイン含有蛋白質１（ａｒｒｄｃ１）コンストラクト
WO2021072328A1 (en) 2019-10-10 2021-04-15 The Broad Institute, Inc. Methods and compositions for prime editing rna
WO2021108717A2 (en) 2019-11-26 2021-06-03 The Broad Institute, Inc Systems and methods for evaluating cas9-independent off-target editing of nucleic acids
JP7826199B2 (ja) 2019-12-03 2026-03-09 ビーム セラピューティクス インク． 合成ガイドｒｎａ、組成物、方法、およびそれらの使用
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
WO2021155065A1 (en) 2020-01-28 2021-08-05 The Broad Institute, Inc. Base editors, compositions, and methods for modifying the mitochondrial genome
US20230235309A1 (en) 2020-02-05 2023-07-27 The Broad Institute, Inc. Adenine base editors and uses thereof
EP4707398A2 (de) 2020-02-05 2026-03-11 The Broad Institute, Inc. Geneditierungsverfahren zur behandlung von spinaler muskelatrophie
US20230159913A1 (en) 2020-04-28 2023-05-25 The Broad Institute, Inc. Targeted base editing of the ush2a gene
AU2021264007A1 (en) 2020-05-01 2022-12-08 Siwa Corporation Methods of treating infections
JP2023525304A (ja) 2020-05-08 2023-06-15 ザ ブロード インスティテュート，インコーポレーテッド 標的二本鎖ヌクレオチド配列の両鎖同時編集のための方法および組成物
AU2021310950A1 (en) 2020-07-24 2023-02-16 President And Fellows Of Harvard College Enhanced virus-like particles and methods of use thereof for delivery to cells
WO2022093195A1 (en) 2020-10-27 2022-05-05 Siwa Corporation Methods and compositions for treating osteoarthritis using anti-age antibodies or age antigens
EP4237556A2 (de) 2020-10-28 2023-09-06 Children's Medical Center Corporation Verkürztes modifiziertes rekombinantes adamts13 und verwendungen davon
US20240000930A1 (en) 2020-12-09 2024-01-04 Siwa Corporation Methods and compositions for treating kidney diseases
KR20230158476A (ko) 2021-02-19 2023-11-20 빔 테라퓨틱스, 인크. 유전자 요법을 위한 재조합 광견병 바이러스
AU2022245243A1 (en) 2021-03-23 2023-09-28 Beam Therapeutics Inc. Novel crispr enzymes, methods, systems and uses thereof
KR20240007651A (ko) 2021-04-16 2024-01-16 빔 테라퓨틱스, 인크. 간세포의 유전적 변형
WO2022256578A2 (en) 2021-06-02 2022-12-08 Beam Therapeutics Inc. Circular guide rnas for crispr/cas editing systems
US20240287487A1 (en) 2021-06-11 2024-08-29 The Broad Institute, Inc. Improved cytosine to guanine base editors
KR20240037299A (ko) 2021-07-23 2024-03-21 빔 테라퓨틱스, 인크. Crispr/cas 편집 시스템용 가이드 rna
CA3229602A1 (en) 2021-08-20 2023-02-23 Siwa Corporation Methods and compositions for treating fibrotic diseases
AU2022343725A1 (en) 2021-09-08 2024-03-21 Beam Therapeutics Inc. Viral guide rna delivery
US20240417719A1 (en) 2021-10-25 2024-12-19 The Broad Institute, Inc. Methods and compositions for editing a genome with prime editing and a recombinase
US20250002945A1 (en) 2021-11-23 2025-01-02 Cellectis Sa New tale protein scaffolds with improved on-target/off-target activity ratios
US20250382334A1 (en) 2021-12-03 2025-12-18 The Broad Institute, Inc. Self-assembling virus-like particles for delivery of nucleic acid programmable fusion proteins and methods of making and using same
WO2023102538A1 (en) 2021-12-03 2023-06-08 The Broad Institute, Inc. Self-assembling virus-like particles for delivery of prime editors and methods of making and using same
CN119095968A (zh) 2021-12-17 2024-12-06 比姆医疗股份有限公司 Crispr酶、方法、系统及其用途
AU2023248451A1 (en) 2022-04-04 2024-10-17 President And Fellows Of Harvard College Cas9 variants having non-canonical pam specificities and uses thereof
WO2023196772A1 (en) 2022-04-04 2023-10-12 Beam Therapeutics Inc. Novel rna base editing compositions, systems, methods and uses thereof
WO2023205687A1 (en) 2022-04-20 2023-10-26 The Broad Institute, Inc. Improved prime editing methods and compositions
CN120456933A (zh) 2022-04-28 2025-08-08 布罗德研究所股份有限公司 编码碱基编辑器的aav载体及其用途
CA3255335A1 (en) 2022-05-27 2023-11-30 President And Fellows Of Harvard College IMPROVED MITOCHONDRIAL BASIS EDITORS AND MITOCHONDRIAL DNA EDITING METHODS
WO2023240137A1 (en) 2022-06-08 2023-12-14 The Board Institute, Inc. Evolved cas14a1 variants, compositions, and methods of making and using same in genome editing
AU2023325079A1 (en) 2022-08-16 2025-02-13 President And Fellows Of Harvard College Evolved cytosine deaminases and methods of editing dna using same
EP4587560A1 (de) 2022-09-16 2025-07-23 Beam Therapeutics Inc. Grosse serinrekombinasen, systeme und verwendungen davon
WO2024077267A1 (en) 2022-10-07 2024-04-11 The Broad Institute, Inc. Prime editing methods and compositions for treating triplet repeat disorders
WO2024102157A1 (en) 2022-11-09 2024-05-16 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
WO2024138087A2 (en) 2022-12-23 2024-06-27 The Broad Institute, Inc. Methods and compositions for modulating cellular factors to increase prime editing efficiencies
EP4652272A1 (de) 2023-01-18 2025-11-26 The Broad Institute Inc. Prime-editierungsvermitteltes durchlesen von codons mit vorzeitiger terminierung (pert)
WO2024155745A1 (en) 2023-01-18 2024-07-25 The Broad Institute, Inc. Base editing-mediated readthrough of premature termination codons (bert)
WO2024168147A2 (en) 2023-02-09 2024-08-15 The Broad Institute, Inc. Evolved recombinases for editing a genome in combination with prime editing
WO2024206125A1 (en) 2023-03-24 2024-10-03 The Broad Institute, Inc. Use of prime editing for treating sickle cell disease
IL324792A (en) 2023-05-23 2026-01-01 Broad Inst Inc Evolved and engineered prime editors with improved editing efficiency
WO2025059202A1 (en) 2023-09-11 2025-03-20 Novavax, Inc. Method for detecting anti-sars-cov-2 spike (s) immunoglobulins
WO2025064678A2 (en) 2023-09-20 2025-03-27 The Broad Institute, Inc. Prime editing-mediated readthrough of frameshift mutations (perf)
WO2025081042A1 (en) 2023-10-12 2025-04-17 Renagade Therapeutics Management Inc. Nickase-retron template-based precision editing system and methods of use
US20250144200A1 (en) 2023-11-06 2025-05-08 Novavax, Inc. Intranasal immunogenic compositions
WO2025106677A1 (en) 2023-11-15 2025-05-22 Slate Bio, Inc. Bifunctional il-2 and il-33 proteins for treating autoimmune disease
WO2025106685A1 (en) 2023-11-15 2025-05-22 Slate Bio, Inc. Interleukin-2 superkine and interleukin-33, compositions and uses thereof
WO2025106663A1 (en) 2023-11-15 2025-05-22 Slate Bio, Inc. Interleukin-33 variants, compositions and uses thereof
WO2025188687A1 (en) 2024-03-04 2025-09-12 Beam Therapeutics Inc. Stable rna compositions with stem loop, and methods thereof
WO2025259863A1 (en) 2024-06-12 2025-12-18 Orbital Therapeutics, Inc. Thermostable ribonuclease r for circular rna purification
WO2026024856A2 (en) 2024-07-23 2026-01-29 The Broad Institute, Inc. Compositions and methods for production of double-stranded dna in cells for programmable gene integration
WO2026046724A1 (en) 2024-08-30 2026-03-05 Cellectis Sa Tale protein scaffolds involving fusions of monopartite and bipartite nls

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3957971A (en) * 1974-07-29 1976-05-18 Lever Brothers Company Moisturizing units and moisturizing compositions containing the same
FR2408387A2 (fr) * 1975-06-30 1979-06-08 Oreal Compositions a base de dispersions aqueuses de spherules lipidiques
FR2315991A1 (fr) * 1975-06-30 1977-01-28 Oreal Procede de fabrication de dispersions aqueuses de spherules lipidiques et nouvelles compositions correspondantes
GB1578776A (en) * 1976-06-10 1980-11-12 Univ Illinois Hemoglobin liposome and method of making the same
US4217344A (en) * 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4356167A (en) * 1978-01-27 1982-10-26 Sandoz, Inc. Liposome drug delivery systems
FR2416008A1 (fr) * 1978-02-02 1979-08-31 Oreal Lyophilisats de liposomes
US4377567A (en) * 1978-10-02 1983-03-22 The Procter & Gamble Company Lipid membrane drug delivery
US4241046A (en) * 1978-11-30 1980-12-23 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
FR2465780A1 (fr) * 1979-09-18 1981-03-27 Oreal Nouveaux tensio-actifs non ioniques, leur procede de preparation et composition les contenant
EP0032622B1 (de) * 1979-12-20 1985-08-14 Dennis Chapman Polymerisationsfähige Phospholipide und deren Polymere, Verfahren zu deren Herstellung, Verfahren zu deren Verwendung für die Bildung von Überzugschichten auf Substraten und zum Bilden von Liposomen und die daraus entstehenden Liposomzusammensetzungen und Substrate mit Überzugschichten
EP0032578B1 (de) * 1980-01-16 1984-07-25 Hans Georg Prof. Dr. Weder Verfahren und Dialysiereinrichtung zur Herstellung von Bilayer-Vesikeln und Verwendung der Bilayer-Vesikel
FR2485921A1 (fr) * 1980-07-01 1982-01-08 Oreal Composition cosmetique a base d'une dispersion aqueuse de spherules lipidiques
DE3161962D1 (en) * 1980-07-01 1984-02-23 Oreal Process for obtaining stable dispersions in an aqueous phase of at least a water immiscible liquid phase, and corresponding dispersions
US4564599A (en) * 1982-08-23 1986-01-14 The Liposome Company, Inc. Liposome composition for lupus assay
JPS5916534A (ja) * 1982-07-19 1984-01-27 Lion Corp 非イオン性界面活性剤系ベシクル分散液
US4551288A (en) * 1982-08-16 1985-11-05 Sandoz, Inc. Processes for the preparation of liposome drug delivery systems
US4485054A (en) * 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
JPS59106423A (ja) * 1982-12-08 1984-06-20 Hiroshi Kiwada リポソ−ム
FR2543018B1 (fr) * 1983-03-22 1985-07-26 Oreal Procede de preparation de vesicules lipidiques par vaporisation de solvants
JPS6072831A (ja) * 1983-09-29 1985-04-24 Kao Corp ベシクル用組成物
JPS6072830A (ja) * 1983-09-29 1985-04-24 Kao Corp ベシクル用組成物
FR2553002B1 (fr) * 1983-10-06 1992-03-27 Centre Nat Rech Scient Procede perfectionne d'obtention de liposomes unilamellaires de diametres eleves, leur application pharmacologique pour l'encapsulage d'un principe actif en vue de son administration extemporanee et dispositif correspondant
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
US4695554A (en) * 1984-02-14 1987-09-22 Becton Dickinson And Company Sac or liposome containing dye (sulforhodamine) for immunoassay
US4610868A (en) * 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US4619913A (en) * 1984-05-29 1986-10-28 Matrix Pharmaceuticals, Inc. Treatments employing drug-containing matrices for introduction into cellular lesion areas
FR2571963B1 (fr) * 1984-10-24 1987-07-10 Oreal Composition a usage cosmetique ou pharmaceutique contenant des niosomes et au moins un polyamide hydrosoluble et procede de preparation de cette composition.
JPS61207324A (ja) * 1985-03-11 1986-09-13 Agency Of Ind Science & Technol リポソ−ム

Also Published As

Publication number Publication date
DK633388A (da) 1988-11-11
CA1289419C (en) 1991-09-24
NO885032D0 (no) 1988-11-11
NO885032L (no) 1988-11-11
KR890700339A (ko) 1989-04-24
NZ223843A (en) 1990-04-26
US4911928A (en) 1990-03-27
AU1541688A (en) 1988-10-10
KR960009647B1 (en) 1996-07-23
AU605581B2 (en) 1991-01-17
EP0352282A1 (de) 1990-01-31
JP2589173B2 (ja) 1997-03-12
WO1988006883A1 (en) 1988-09-22
DK633388D0 (da) 1988-11-11
DE3867637D1 (de) 1992-02-20
HUT53279A (en) 1990-10-28
EP0352282B1 (de) 1992-01-08
JPH02502094A (ja) 1990-07-12
BR8807410A (pt) 1990-04-10

Similar Documents

Publication Publication Date Title
ATE71289T1 (de) Paucilamellare lipidvesikel.
DK433484D0 (da) Medikamentholdigt lipidvesikelpraeparat
DE3861772D1 (de) Verfahren fuer die herstellung von stabilen oeligen zusammensetzungen.
NO885605L (no) Fremgangsmaate for fremstilling av smoereolje.
NO884310L (no) Fremgangsmaate for fremstilling av noeytralt papir.
PT88754A (pt) Method of making three-layer paper
DK164483C (da) Fremgangsmaade til opbevaring af phospholipid liposomer
IT8021372A0 (it) Processo per la preparazione di perossidi alcalini o alcalinoterrosi.
IT8119862A0 (it) Corredo per la misurazione di perossidi lipidici.
DE3777711D1 (de) Herstellung von gegenstaenden unter verwendung von phosphorglaesern.
IT8421885A0 (it) Procedimento per la produzione di alcoli.
DK554289A (da) Helium-neonlaser
ES2014481B3 (es) Procedimiento para la fabricacion de vidrieras laminadas.
DE3886915D1 (de) Raman-hohlraumlaser.
DE3872875D1 (de) Verfahren zur herstellung von liposomen.
IT1176953B (it) Procedimento per la produzione di poliesteri aromatici
FI874879A7 (fi) Menetelmä mekaanisen massan valmistuksessa.
DE3872874D1 (de) Verfahren zur herstellung von liposomen.
DE3850601D1 (de) Verfahren zur Herstellung von Phospholipidderivate.
IT8867697A0 (it) Procedimento per provocare la rottura di una emulsione
IT1143019B (it) Procedimento per la preparazione di agenti di collatura per carta
ES531129A0 (es) Procedimiento para aislar agentes tensioactivos lipidicos
ES2126868T3 (es) Liposomas de fusion por interdigitacion que contienen metabolitos de acido araquidonico.
ES1005242Y (es) Microscopio simplificado
GR1000471B (el) Μεθοδος παρασκευης κινολινοθειοαιθερων.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee